The complexity of drug development for irritable bowel syndrome

@article{Kamm2002TheCO,
  title={The complexity of drug development for irritable bowel syndrome},
  author={M. Kamm},
  journal={Alimentary Pharmacology & Therapeutics},
  year={2002},
  volume={16}
}
  • M. Kamm
  • Published 2002
  • Medicine
  • Alimentary Pharmacology & Therapeutics
    • Drug development for functional gastrointestinal disorders is complex. These conditions involve central and peripheral physiological changes, together with psychological factors. Methodological problems have included a poor appreciation of the physiological and psychological correlates of patients' symptoms, a lack of animal models of proven relevance, and safety issues. Government, patient pressure groups and the Internet can also influence a drug's success. Most recent interest has focused on… CONTINUE READING
    View on Wiley
    onlinelibrary.wiley.com
    47 Citations
    Highly Influencial Citations
    2
    Background Citations
    14
    Methods Citations
    1
    Results Citations
    1
    47 Citations
    Citation Type

    Citation Type

    New pharmacological treatment options for irritable bowel syndrome with constipation
    • 9
    Alosetron in Irritable Bowel Syndrome
    • 6
    New developments in the diagnosis and treatment of irritable bowel syndrome
    • 17
    Evaluation of drug treatment in irritable bowel syndrome.
    • N. Talley
    • Medicine
    • British journal of clinical pharmacology
    • 2003
    • 65
    Novel strategies and future landmarks in the treatment of irritable bowel syndrome
    Tegaserod in the treatment of constipation-predominant functional gastrointestinal disorders
    Serotonergic agents in the treatment of functional gastrointestinal disorders
    • 1
    Safety and tolerability of tegaserod in irritable bowel syndrome management.
    • R. Berardi
    • Medicine
    • Journal of the American Pharmacists Association : JAPhA
    • 2004
    • 7
    Benefit-Risk Assessment of Tegaserod in Irritable Bowel Syndrome
    • 7
    Role of serotonin in the pathophysiology of the irritable bowel syndrome
    • M. Crowell
    • Medicine, Biology
    • The American journal of managed care
    • 2001
    • 205

    References

    SHOWING 1-10 OF 34 REFERENCES
    Entry criteria for drug trials of irritable bowel syndrome.
    • M. Kamm
    • Medicine
    • The American journal of medicine
    • 1999
    • 9
    Review article: clinical evidence to support current therapies of irritable bowel syndrome
    • M. Camilleri
    • Medicine
    • Alimentary pharmacology & therapeutics
    • 1999
    • 41
    Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial
    • 549
    Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron).
    • 88
    Psychometric scores and persistence of irritable bowel after infectious diarrhoea.
    • T. King
    • Medicine
    • Clinical nutrition
    • 1996
    • 193
    Functional gastrointestinal disorders.
    • J. Hyams
    • Medicine
    • Current opinion in pediatrics
    • 1999
    • 283
    Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers
    • 100
    • PDF
    Antidepressant therapy in 138 patients with irritable bowel syndrome: a five‐year clinical experience
    • 157
    Review article: tegaserod.
    • M. Camilleri
    • Medicine
    • Alimentary pharmacology & therapeutics
    • 2001
    • 182
    What is the benefit of coarse wheat bran in patients with irritable bowel syndrome?
    • 164
    • PDF